Pomerantz LLP has filed a class action lawsuit against Embecta Corp. over potential securities fraud. Investors who purchased or acquired Embecta securities during the class period have until August 17, 2026, to seek appointment as lead plaintiff. The lawsuit follows Embecta's May 5, 2026, announcement of second-quarter fiscal 2026 results, which revealed a revenue decline of over 14%—far exceeding prior guidance of flat to a 2% decline—and lowered full-year guidance, partly due to weakness in pen needle sales. On that news, Embecta's stock price fell nearly 58%, harming investors.
Embecta CorpClass action lawsuit and revenue decline of over 14% with lowered guidance caused stock to fall nearly 58%